FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer

On February 26, 2018, the Food and Drug Administration approved abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BVaz28
via IFTTT